SML1617

GSK2033

≥98% (HPLC), nuclear receptor liver-X-receptor (LXR) antagonist, powder

• Synonim(y): 2,4,6-Trimethyl-N-[[3′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide
• Wzór empiryczny (zapis Hilla): C₂₉H₂₈F₃NO₅S₂
• Numer CAS: 1221277-90-2
• Masa cząsteczkowa: 591.66
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825503
• NACRES: NA.77
• MDL number: MFCD28396416
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: GSK2033, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 3 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: CS(C1=CC=CC(C2=CC=C(CN(S(C3=C(C)C=C(C)C=C3C)(=O)=O)CC4=CC=C(C(F)(F)F)O4)C=C2)=C1)(=O)=O
• InChI: 1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3
• InChI key: PSOXOVKYGWBTPB-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

GSK2033 is an antagonist of the nuclear receptor liver-X-receptor (LXR) with pIC50 values of 7.0 for LXRα and 7.4 for LXRβ. Treatment of murine CD41 T cells with GSK2033 enhanced cellular proliferation and Th1/Th2/Th17 differentiation. In another study, the conjugated linoleic acid (CLA)-induced expression of efflux protein ATP-binding-cassette transporter A1 (ABCA1) was completely abolished by preincubation with GSK2033, showing that CLA mediated regulation of ABCA-1 expression is LXR dependent.

LXR antagonist

GSK2033 has the ability to repress gluconeogenic gene expression stimulated by GC (glucocorticoids), without altering immune-responsive GR (GC receptor) target genes. It helps to target several nuclear receptors that can alter hepatic gene expression.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable